Triple Agonists (GLP-1/GIP/Glucagon) Drug-Drug Interaction Table At a glance Prototype drug / retatrutide (LY3437943) Mechanism / simultaneous GLP-1R, GIPR, and glucagon receptor agonism Phase 2 weight loss (48 wk) / 24.2% mean body weight reduction vs 2.1% placebo Primary metabolic targets / obesity, MASLD/MASH, T2D, dyslipidemia Gastric emptying effect / marked slowing, peak drug interaction risk 1 to 4 h post-dose Oral drug most affected / warfarin, oral contraceptives, levothyroxine, cyclosporine Hypoglycemia risk / low monotherapy
Liu, Q., Kriksunov, I
If youre considering IV therapy for weight loss, we help you use it smartly, alongside diet and exercise
Several amino acids particularly methionine, cysteine, and tryptophan are susceptible to oxidation
Want to be up-to-date with the research in sports nutrition